Clinical Trial Update: AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the combination of bevacizumab and bemarituzumab for gynecologic cancers (endometrial, ovarian, and cervical) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• Bemarituzumab (bemarituzumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Centre Leon Berard | Conditions: Endometrial Carcinoma, Ovarian Cancer | Phase 1, Phase 2 | Status: WITHDRAWN